Skip to main content
SpringerLink
Log in

Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope

  • Chapter
  • First Online:
Biomedical Translational Research

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the approach to cancer management in the recent decade. In the physiological state, the dynamic interplay between persistent death receptor 1 and its ligand modulates the immune tolerance to self-antigens and adaptive immune response to neoantigens. The rapid development and regulatory approval of newer immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 lead to a paradigm shift in primary cancer treatments, with some of them achieving a cure. Despite striking and sustainable responses in most patients, eventually, they develop treatment resistance and cancer progression. The factors for the prediction of clinical efficacy of checkpoint inhibitors are complex and evolving. This chapter features immune checkpoint inhibitors in solid cancer management and prediction of treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA et al (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 Study. J Clin Oncol 38(18_Suppl):LBA4

    Article  Google Scholar 

  • Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL et al (2018) Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428–1439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Balar AV et al (2020) Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). J Clin Oncol [Internet]. [Cited 2020 Sept 8]. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.350

  • Bang Y-J, Kang Y-K, Catenacci DV, Muro K, Fuchs CS, Geva R et al (2019) Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 22(4):828–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG et al (1987) A new member of the immunoglobulin superfamily—CTLA-4. Nature 328(6127):267–270

    Article  CAS  PubMed  Google Scholar 

  • Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928

    Article  CAS  PubMed  Google Scholar 

  • Chen T-T (2015) Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors. J Natl Cancer Inst 107(9):djv156

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31(8):1030–1039

    Article  CAS  PubMed  Google Scholar 

  • Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37(17):1470–1478

    Article  CAS  PubMed  Google Scholar 

  • Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH et al (2020) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15(4):618–627

    Article  CAS  PubMed  Google Scholar 

  • D’Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P et al (2020) Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer 8(1):e000674

    Article  PubMed  PubMed Central  Google Scholar 

  • Diaz LA, Le D, Maio M, Ascierto PA, Geva R, Motola-Kuba D et al (2019) Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies. Ann Oncol 30:v475

    Article  Google Scholar 

  • Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson V, Dalle S et al (2020) Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. J Clin Oncol 38(15_Suppl):10000

    Article  Google Scholar 

  • El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S et al (2018) Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 13(8):1156–1170

    Article  CAS  PubMed  Google Scholar 

  • Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med [Internet] 382(20):1894–1905. [Cited 2020 Sept 9]. https://www.nejm.org/doi/10.1056/NEJMoa1915745

    Article  CAS  Google Scholar 

  • Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38(14):1505–1517

    Article  CAS  PubMed  Google Scholar 

  • Gettinger S, Borghaei H, Brahmer J, Chow L, Burgio M, Carpeno JDC et al (2019) OA14.04 five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. J Thorac Oncol 14(10):S244–S245

    Article  Google Scholar 

  • Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G (2019) Ovarian cancer immunotherapy: turning up the heat. Int J Mol Sci [Internet] 20(12):2927. [Cited 2020 Aug 30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628106/

    Article  CAS  Google Scholar 

  • Gray JE, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R et al (2019) Three-year overall survival update from the PACIFIC trial. J Clin Oncol 37(15_Suppl):8526–8526

    Article  Google Scholar 

  • Grob JJ, Gonzalez Mendoza R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A et al (2019) LBA72—pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): efficacy and safety results from the phase II KEYNOTE-629 study. Ann Oncol 30:v908

    Article  Google Scholar 

  • Gunasekaran M, Russo A, Cardona AF, Perez D d M, Lapidus R, Cooper B et al (2020) Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. J Immunol 204(1 Suppl):90.10

    Google Scholar 

  • Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S et al (2020) Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395(10240):1835–1844

    Article  CAS  PubMed  Google Scholar 

  • Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • He AR, Yau T, Hsu C, Kang Y-K, Kim T-Y, Santoro A et al (2020) Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): subgroup analyses from CheckMate 040. J Clin Oncol 38(4_Suppl):512

    Article  Google Scholar 

  • Heemskerk B, Kvistborg P, Schumacher TNM (2013) The cancer antigenome. EMBO J 32(2):194–203

    Article  CAS  PubMed  Google Scholar 

  • Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020–2031

    Article  CAS  PubMed  Google Scholar 

  • Herbst R, Marinis FD, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C et al (2020a) O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC. J Immunother Cancer [Internet] 8(Suppl 1). [Cited 2020 Sept 9]. https://jitc.bmj.com/content/8/Suppl_1/A1.1

  • Herbst RS, Garon EB, Kim D-W, Cho BC, Perez-Gracia JL, Han J-Y et al (2020b) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 38(14):1580–1590

    Article  CAS  PubMed  Google Scholar 

  • Horn L, Mansfield AS, SzczÄ™sna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  PubMed  Google Scholar 

  • Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC et al (2020) Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol 21(8):e398–e404

    Article  CAS  PubMed  Google Scholar 

  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

    Article  CAS  PubMed  Google Scholar 

  • Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH et al (2020) Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 38(4_Suppl):518

    Article  Google Scholar 

  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546

    Article  CAS  PubMed  Google Scholar 

  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lenz H-J et al (2020) Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol [Internet]. [Cited 2020 Sept 8]. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.11

  • Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS et al (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27(10):1953–1958

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1–10

    Article  CAS  PubMed  Google Scholar 

  • Meeting Library | Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. [Internet]. [Cited 2020 Sept 9]. https://meetinglibrary.asco.org/record/186872/abstract

  • Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370–1385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Motzer RJ, Tykodi SS, Escudier B, Oudard S, Hammers HJ, McDermott DF et al (2020) Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J Clin Oncol 38(6_Suppl):617

    Article  Google Scholar 

  • Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS et al (2019) Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol 37(9):693–702

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP et al (2017) Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med 9(393):eaal4922

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y et al (2019) Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol 24(9):1089–1098

    Article  CAS  PubMed  Google Scholar 

  • Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51–64

    Article  CAS  PubMed  Google Scholar 

  • Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J et al (2018) Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 379(21):2040–2051

    Article  CAS  PubMed  Google Scholar 

  • Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (Lond Engl) 394(10212):1929–1939

    Article  CAS  Google Scholar 

  • Powles T, O’Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma. JAMA Oncol [Internet] 3(9):e172411. [Cited 2020 Sept 9]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824288/

    Article  Google Scholar 

  • Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 14(2):237–244

    Article  CAS  PubMed  Google Scholar 

  • Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, CsÅ‘szi T, Fülöp A et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537–546

    Article  CAS  PubMed  Google Scholar 

  • Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(4):934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127

    Article  CAS  PubMed  Google Scholar 

  • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20(9):1239–1251

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (Lond Engl) 387(10031):1909–1920

    Article  CAS  Google Scholar 

  • Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59

    Article  CAS  PubMed  Google Scholar 

  • Schnipper LE, Schilsky RL (2018) Are value frameworks missing the mark when considering long-term benefits from immuno-oncology drugs? JAMA Oncol 4(3):333–334

    Article  PubMed  Google Scholar 

  • Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74

    Article  CAS  PubMed  Google Scholar 

  • Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol [Internet] 8:86. [Cited 2020 Sept 8]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883082/

    Article  Google Scholar 

  • Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152

    Article  PubMed  PubMed Central  Google Scholar 

  • Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A et al (2019) Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol 5(4):546–550

    Article  PubMed  Google Scholar 

  • Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301

    Article  CAS  PubMed  Google Scholar 

  • Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E et al (2015) Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3(9):1052–1062

    Article  CAS  PubMed  Google Scholar 

  • The Nobel Prize in Physiology or Medicine (2018) [Internet]. NobelPrize.org. [Cited 2020 Sept 6]. https://www.nobelprize.org/prizes/medicine/2018/summary/

  • Vuky J, Balar AV, Castellano D, O’Donnell PH, Grivas P, Bellmunt J et al (2020) Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 38(23):2658–2666

    Article  CAS  PubMed  Google Scholar 

  • Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824–1835

    Article  CAS  PubMed  Google Scholar 

  • Zinzani PL, Lee HJ, Armand P, Johnson N, Brice P, Radford J et al (2019) Three-year follow-up of Keynote-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood 134(Suppl_1):240

    Article  Google Scholar 

  • Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumor microenvironment. Nat Rev Immunol 8(6):467–477

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Sciences and Research, Chandigarh, India

    Chandan Krushna Das

  2. Department of Urology, Post graduate Institute of Medical Education and Research, Chandigarh, India

    Shrawan K. Singh

Authors
  1. Chandan Krushna Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shrawan K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biotechnology, Punjab University, Chandigarh, India

    R.C. Sobti

  2. Department of Pathology, University of Miami Health System, Florida, USA

    Awtar Krishan Ganju

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Das, C.K., Singh, S.K. (2022). Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. In: Sobti, R., Ganju, A.K. (eds) Biomedical Translational Research. Springer, Singapore. https://doi.org/10.1007/978-981-16-8845-4_20

Download citation

Publish with us

Policies and ethics

Search

Navigation